Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma regression mediated by bruceantin.

Muriel Cuendet1, Konstantin Christov, Daniel D Lantvit

  • 1Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 12, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and characterization of a resveratrol spray-dried inhalable formulation for pulmonary delivery with <i>in vivo</i> pharmacokinetic and toxicological evaluation.

Drug delivery·2026
Same author

Suppression of mitochondrial energy production by a photosynthetic bacterial cupredoxin peptide inhibits tumor growth.

Signal transduction and targeted therapy·2026
Same author

Efficacy and safety ranking of endoscopic resection techniques for colorectal polyps: a systematic review and network meta-analysis.

Therapeutic advances in gastroenterology·2026
Same author

Activity of Didesmethylrocaglamide in High Grade Serous Ovarian Cancer Using Preclinical In Vitro and In Vivo Models.

Journal of natural products·2026
Same author

Platelet-rich plasma promotes cellular recovery from nicotine-induced toxicity via autophagy modulation.

Scientific reports·2026
Same author

Association between cholecystectomy/gallbladder pathology and colorectal polyps: a systematic review and meta-analysis.

Frontiers in oncology·2026

Bruceantin effectively inhibits multiple myeloma cell growth and induces apoptosis in both cell cultures and animal models. These findings suggest its potential for treating hematological malignancies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Bruceantin has demonstrated efficacy in inducing cell differentiation and down-regulating c-MYC in leukemia and lymphoma cell lines.
  • The precise mechanisms and therapeutic potential of bruceantin in multiple myeloma remain to be fully elucidated.

Purpose of the Study:

  • To investigate the effects of bruceantin on multiple myeloma cell line RPMI 8226.
  • To evaluate the impact of bruceantin on c-MYC expression, apoptosis, and tumor growth in a multiple myeloma model.

Main Methods:

  • Immunoblotting and 4',6-diamidino-2-phenylindole staining were used to assess c-MYC levels and apoptosis.
  • Caspase activity and mitochondrial pathways were evaluated to understand apoptosis mechanisms.
  • RPMI 8226 xenografts in SCID mice were used to assess tumor growth inhibition and apoptosis via terminal deoxynucleotidyl transferase-mediated nick end labeling assay.

Related Experiment Videos

Main Results:

  • Bruceantin significantly down-regulated c-MYC in RPMI 8226 cells, but not in U266 or H929 cells.
  • Apoptosis was induced in all tested cell lines, involving caspase activation and the mitochondrial pathway.
  • Bruceantin treatment led to significant regression of RPMI 8226 xenografts with elevated apoptosis in tumors, without apparent toxicity.

Conclusions:

  • Bruceantin demonstrates potent anti-proliferative effects on multiple myeloma cells in vitro and in vivo.
  • The compound effectively induces apoptosis and inhibits tumor growth in a multiple myeloma xenograft model.
  • These findings warrant further investigation into bruceantin's clinical efficacy for multiple myeloma and other hematological malignancies.